All Photos(1)

Documents

Y0000598

Medroxyprogesterone acetate for system suitability

Name: Medroxyprogesterone acetate for system suitability
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Medroxyprogesterone 17-acetate, 17α-Acetoxy-6α-methylprogesterone, 17α-Hydroxy-6α-methyl-4-pregnene-3,20-dione 17-acetate, 6α-Methyl-17α-acetoxyprogesterone, 6α-Methyl-17α-hydroxyprogesterone acetate

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₂₄H₃₄O₄

CAS Number:

71-58-9

Molecular Weight:

386.52

Beilstein/REAXYS Number:

2066112

MDL number:

MFCD00010483

UNSPSC Code:

41116107

PubChem Substance ID:

329831042

NACRES:

NA.24

Recommended Products

Slide 1 of 10

1 of 10

Y0000349

Insulin aspart

Supelco

PHR1589

Medroxyprogesterone Acetate

M0250000

Medroxyprogesterone acetate

Sigma-Aldrich

D2650

Dimethyl sulfoxide

Supelco

91816

HPTLC calibration mix

USP

1342037

Insulin aspart

GF48562465

Aluminum

Y0001514

Megestrol acetate

Y0001524

Megestrol acetate for system suitability

Sigma-Aldrich

D1692

GW4869

grade

pharmaceutical primary standard

API family

medroxyprogesterone

manufacturer/tradename

EDQM

mp

206-207 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

[H][C@@]12C[C@H](C)C3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@@]4(C)[C@@]2([H])CC[C@]4(OC(C)=O)C(C)=O

InChI

1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1

InChI key

PSGAAPLEWMOORI-PEINSRQWSA-N

Gene Information

human ... PGR(5241)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Medroxyprogesterone acetate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Related product

Product No.

Description

Pricing

signalword

Warning

hcodes

H351,H413

pcodes

P202 - P273 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Aquatic Chronic 4 - Carc. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pregnancy outcomes after fertility-sparing management in young women with early endometrial cancer.

Jeong-Yeol Park et al.

Obstetrics and gynecology, 121(1), 136-142 (2012-12-25)

To analyze pregnancy outcomes in young women with stage IA, grade 1 endometrioid adenocarcinoma of the uterus after successful fertility-sparing management using progestin. We reviewed the medical records of 141 women with stage IA, grade 1 endometrioid adenocarcinoma of the

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.

JoAnn E Manson et al.

JAMA, 310(13), 1353-1368 (2013-10-03)

Menopausal hormone therapy continues in clinical use but questions remain regarding its risks and benefits for chronic disease prevention. To report a comprehensive, integrated overview of findings from the 2 Women's Health Initiative (WHI) hormone therapy trials with extended postintervention

Hormonal contraception and HIV-1 infection: medroxyprogesterone acetate suppresses innate and adaptive immune mechanisms.

Richard P H Huijbregts et al.

Endocrinology, 154(3), 1282-1295 (2013-01-29)

Recent observational studies indicate an association between the use of hormonal contraceptives and acquisition and transmission of HIV-1. The biological and immunological mechanisms underlying the observed association are unknown. Depot medroxyprogesterone acetate (DMPA) is a progestin-only injectable contraceptive that is

The contraceptive depot medroxyprogesterone acetate impairs mycobacterial control and inhibits cytokine secretion in mice infected with Mycobacterium tuberculosis.

Léanie Kleynhans et al.

Infection and immunity, 81(4), 1234-1244 (2013-02-06)

The contraceptive depot medroxyprogesterone acetate (DMPA), with progestin as the single active compound, possesses selective glucocorticoid activity and can alter the expression of glucocorticoid receptor-regulated genes. We therefore propose that pharmacological doses of DMPA used for endocrine therapy could have

Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials.

Robert A Wild et al.

Menopause (New York, N.Y.), 20(3), 254-260 (2013-02-26)

Our objective was to determine whether metabolic syndrome (MetS) or its components modified the effect of hormone therapy (HT) on the risk of coronary heart disease (CHD) events in the Women's Health Initiative clinical trials. We performed a nested case-control

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service